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To the Editor:
T-cell prolymphocytic leukemia (T-PLL) is the most frequent
mature T-cell leukemia in Western countries. Its inherently
aggressive growth and a notoriously chemotherapy refractory
behavior result in overall survival times of <20–36 months
[1, 2]. There are no formally licensed drugs for T-PLL.
Although the anti-CD52 monoclonal antibody alemtuzumab
induces high primary response rates, the vast majority of
patients relapse on average within 12 months thereafter [3, 4].
Presentation at a median age of 63 years and post-induction
conditions render 50–70% of patients ineligible for allogeneic
stem cell transplantation. Moreover, long-term disease control
can only be accomplished for a proportion of 20–30% of
transplanted patients. Overall, T-PLL remains an insuffi-
ciently addressed rare entity with urgently needed novel
treatment designs.
The molecular and diagnostic hallmarks of T-PLL are the
chromosomal aberrations inv(14), t(14;14), and t(X;14),
which underlie constitutive expression of the proto-oncogenes
T-cell leukemia/lymphoma 1A (TCL1A) or Mature T-cell
Proliferation 1 (MTCP1). The oncogenic role of both of these
TCL1-family genes was proven in Lck-hTCL1A [5] and CD2-
hMTCP1 [6] transgenic (tg) mice. They develop T-cell
expansions that closely resemble human T-PLL. TCL1A acts
as a coactivator of pro-survival AKT [2].
In a recent comprehensive genomic characterization of
>100 T-PLL, we identified that missense mutations and
monoallelic deletions of Ataxia Telangiectasia Mutated
(ATM) also represent highly recurrent lesions, found in ≈86%
of cases [7]. Besides executing several tumor-suppressive
functions, ATM is best known as the apical regulator of DNA
repair and safeguarding cell fate decisions in an adequate
DNA damage response (DDR). We uncovered an oncogenic
cooperation of overexpressed TCL1A with deficient ATM,
which entails a diminished capacity of T-PLL cells to prop-
erly sense and process DNA double strand breaks [7]. Most
importantly, in light of genomic integrity of TP53, but
hypomorphic ATM in almost all T-PLL, the leukemic cells
failed to generate a sufficient phospho-CHK2/p53 response to
DNA damage [7].
Another enriched cluster of perturbed pathways in T-PLL
are epigenetic regulators [7]. Generally, treatment resistance
in cancer is often linked to an altered epigenetic (e.g.,
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histone) code. Moreover, DDR execution is closely inter-
linked with epigenetic modifications and DNA repair itself
depends on chromatin remodeling through histone
modulations [8]. Furthermore, activation of central DDR
mediators like ATM and p53 involves their immediate
histone-acetyltransferase (HAT) mediated acetylation, which
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is regulated via deacetylation through (histone) deacetylases
((H)DACs) [9, 10]. HDAC inhibitors (HDACiʼs) show
particular activity in T-cell neoplasms [11, 12].
In an initial high-throughput ex vivo drug screen, we
recently showed that HDACi’s perform highly effective as
single substances in T-PLL [13]. Especially with regard to
selective drug sensitivity scores (sDSSʼs) of potentially T-
cell active drug groups (i.e., purines, anthracyclines), the
substance cluster of HDACiʼs showed a high and strong
leukemia-specific efficacy (sDSS= 9.40) in T-PLL samples
(Fig. 1a). In our expanded comparison, classical cytotoxic
drugs proved to be of low efficacy, with bendamustine
(sDSS= 0.85) as the most potent compound among them.
We further postulated that an impaired DDR through dys-
functional ATM, which was not efficiently targetable in
light of a potential synthetic lethal relationship to DNAPK
(Fig. S1), might represent a vital and exploitable aberrancy
in T-PLL in the context of its dependence on HAT/DAC-
regulated acetylation [7]. Thus, to reinstate T-PLL cell
death execution, we conceived a principle of DNA-damage
induction in conjunction with (H)DAC inhibition.
For that, we evaluated a novel alkylating HDACi mole-
cule, the substance EDO- S101 (Fig. 1b, now known as
tinostamustine), as an interventional strategy in defined
in vitro and in vivo readouts. As one functional component,
namely for DNA damage induction, it contains the
nucleoside-like alkylator bendamustine. Single-agent
bendamustine already showed clinical activity in
treatment-naïve and in alemtuzumab-refractory T-PLL [14].
In addition, as a deacetylase-inhibiting moiety, EDO- S101
contains vorinostat, which has proven its efficacy in pilot
clinical trials and is approved by the FDA for the treatment
of cutaneous T-cell lymphoma [12].
Confirming our molecular rationale and indicative of a
functional (H)DACi moiety in EDO- S101, the exposure of
human primary T-PLL cells to EDO-S101 induced high
acetylation levels of histone 3, which exceeded the degree
induced by the (H)DACi vorinostat or by equimolar com-
binations of vorinostat with bendamustine (Fig. 1c).
Moreover, adequate DDRs include proper damage sensing,
repair induction, as well as effective apoptosis execution
upon detection of irreparable DNA lesions. An interference
of EDO-S101 with DDR processes was previously shown
through a downregulation of DNA repair proteins including
RAD51 and BRCA1 [15]. We further demonstrated that
EDO-S101-mediated (H)DAC inhibition and DNA alkyla-
tion led to an increased phospho-activation of ATM and
its substrates KAP1 and histone 2A (H2AX) (Fig. 1c).
EDO-S101-mediated effects on pKAP1 and yH2AX were
superior to those by the simultaneous application of both
single substances (36 h incubation with equimolar combi-
nations). This finding suggests reinduction of ATM-
mediated downstream signaling in primary T-PLL through
DAC inhibition. In order to evaluate induction of pro-
apoptotic signaling in response to EDO-S101 treatment,
we evaluated p53 phosphorylation/acetylation and Poly
(ADP-Ribose)-Polymerase (PARP) cleavage. EDO-S101
reinstated the lost p53 phosphorylation/acetylation response
Fig. 1 Principle of (H)DAC inhibition combined with DNA
damage induction in a single agent reinstates p53 activation and
reduces T-PLL cell survival. a Comparison of average sDSSʼs across
39 human T-PLL samples between different groups of cytotoxic drugs.
Mean sDSS values of all substances of the same group were plotted as
dots in the pirate plots, hence each dot represents the response of one
T-PLL sample to that group. Numeric values depict median sDSS’s for the
compound groups (mean with 95% CI, SEM). Purines: cladribine, flu-
darabine, mercaptopurine, pentostatin, and thioguanine. Anthracyclines:
doxorubicin and mitoxantrone. Pyrimidines: cytarabine, floxuridine, and
fluorouracil. HDACiʼs: vorinostat, quisinostat, panobinostat, CUDC-101,
and belinostat. sDSS: selective drug sensitivity score, representing
leukemia-specific responses; calculated by deduction of median DSS of
healthy-donor mononuclear cell controls (n= 4) from the DSS’s of T-PLL
samples [17]. CTX: cyclophosphamide, ATC: anthracyclines, Pyrimid.:
pyrimidines, Benda.: bendamustine, HDACi’s: histone deacetylase inhi-
bitors. b Structure of EDO-S101: covalent fusion of bendamustine (green)
and the pan-HDACi vorinostat (blue). c Primary T-PLL cells isolated from
patient’s peripheral blood (PB) were treated in suspension cultures with
EDO-S101, vorinostat, bendamustine, and their equimolar single-agent
combination, each at 1 µM for 36 h (one representative immunoblot from
two patients shown). HDAC inhibition via vorinostat enhanced
bendamustine-induced DDR (pKAP1 and γH2AX induction) and trig-
gered apoptotic cascades (cleaved (c) PARP). Exceeding the impact of the
combined single components (vorinostat and bendamustine), equimolar
EDO-S101 showed the highest effects on pATM/pKAP1/γH2AX induc-
tion, on reconstituted acetyl- and p-p53Ser15, on histone-3 acetylation, as
well as on marks of apoptosis (cPARP). d Primary T-PLL cells (14 cases,
suspension cultures) were treated in vitro for 72 h with the fusion molecule
EDO-S101 (0.01–10 µM; LD50= 0.4 µM; range at 0.6 µM: 9–80% via-
bility) and venetoclax (0.0001–0.1 µM; LD50= 0.024 µM; range at 0.03
µM: 14–87% viability). Cell viability was assessed by CellTiter-Glo®
luminescent assay quantifying ATP. Single circles and single squares
represent respective concentration-related dose–responses per sample
(mean with SEM). e Primary T-PLL cells (ten cases, suspension cultures)
were treated with increasing concentrations of EDO-S101, vorinostat,
bendamustine, and the equimolar combination thereof. Dose–response
curves are based on relative numbers of living cells. Cell death was
quantified by AnnV/7AAD staining (p value: survival at 0 µM vs. 1 μM,
paired t-test; mean with SEM). f Primary cells were treated with increasing
concentrations of single-agent bendamustine (dose–response curves);
relative numbers of viable T-PLL cells, healthy-donor derived CD3+
T-cells, and PBMCs in suspension cultures. Cell-death quantification via
AnnV/7AAD staining. g Primary cells exposed to increasing concentra-
tions of EDO-S101 (dose–response curves); concentration-related selective
(vs. normal T-cells/PBMCs) sensitivity of T-PLL toward EDO-S101 with
≈10-fold lower sensitivity of PBMCs (LD50= 10.9 μM). Cell-death
quantification via AnnV/7AAD staining. h Primary T-PLL cells were
treated in the presence of NKtert bone-marrow stromal cells with
increasing concentrations (0.1, 1, or 10 μM) of EDO-S101, vorinostat,
bendamustine, and equimolar combinations of vorinostat with bend-
amustine for 48 h. Cell death was quantified by AnnV/7AAD staining.
EDO-S101 overcame stroma-mediated protective effects (n= 5; paired
t-test; mean with SEM). For higher-resolution titrations in the range of
1–10 µM (accomplishable plasma levels in humans are 3-4 µM) see
Fig. S2d. i EDO-S101 only minimally affected NKtert feeder cell viability
(MTT assays) after 48 h at 0.1, 1, 5, or 10 µM of EDO-S101, vorinostat,
bendamustine, and equimolar combinations of the latter two (three
experiments; mean with SEM).
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and PARP cleavage, which hints at a profound reactivation
of apoptosis. Our findings further strengthen the role of
DAC mediated downregulation of p53 activity in T-PLL
and suggest a proper p53 reactivation via the inhibition of
ATM/p53 deacetylation [10].
Notably, we observed a concentration-related selective
sensitivity of T-PLL cells towards EDO-S101. In studies of
in vitro viability (CellTiter-Glo®, 72 h incubation), exposure
of primary T-PLL cell suspension cultures to increasing
concentrations of EDO-S101 markedly reduced cell viability
(14 cases, LD50= 0.4 µM; Fig. 1d). The inter-individual
variability of this EDO-S101 effect was comparable to the
responses to the potent BCL2 inhibitor venetoclax (Fig. 1d).
Surface CD52 levels were unaltered by EDO-S101 (Fig. S2a).
EDO-S101 also induced specific apoptosis in these T-PLL
cultures as per flow-cytometric analyses of AnnexinV/7-
aminoactinomycin D (AnnV/7AAD; 48 h incubation).
Therein, it showed a more-than-additive potency (LD50=
1.0 μM, p= 0.0002) compared with the ≈4-fold lower sensi-
tivity of the equimolar combination of both of its single
components vorinostat and bendamustine (LD50= 4.4 µM,
p= 0.0028; Fig. 1e, S2b). This might be explained by altered
pharmacodynamics of the merged molecule at the DNA
strand(s). It is conceivable that the HDAC inhibition opens
chromatin regions resulting in better DNA accessibility for the
alkylating component [15]. Following a self-enhancing prin-
ciple, the HDACi part may even gain increased chromatin
access due to the alkylator’s covalent, hence, irreversible
binding to the DNA. Priming by incubation with vorinostat
24 h before the addition of bendamustine was not more effi-
cient in cell-death induction than the simultaneous application
of both single compounds or the exposure to EDO-S101 (n=
4 T-PLL, overall time 48 h, data not shown).
Among these 10 T-PLL samples investigated for
EDO-S101-induced programmed cell death (Fig. 1e), 9 cases
responded to low micro-molar dosages (LD50= 0.8 µM).
Only cells of one patient appeared non-responsive (LD50 > 10
µM) to EDO-S101. However, this case did not stand out with
respect to any of the following parameters: presence of
genomic ATM lesions (mono-allelic losses: 5/10 cases; muta-
tions: 8/9 cases), TP53 lesions (mono-allelic losses: 1/10 cases
(but not the insensitive case); mutations: 0/5 characterized
cases), and clinical exposure to treatment prior to sampling (2/
10 cases). When additionally comparing the rare T-PLL cases
with a genetic (mono-allelic) TP53 loss (n= 3) to those with
TP53 in wild-type constitution, no difference in EDO-S101
mediated apoptosis induction was observed (Fig. S2c).
Cell death induction by EDO-S101 showed favorable spe-
cificity. In contrast to single-agent bendamustine (LD50T-PLL=
7.3 µM; LD50PBMC= 21.5 µM; LD50CD3+ T-cell = 30.8 µM)
(Fig. 1f), EDO-S101 displayed higher selectivity toward T-PLL
cells (LD50T-PLL= 1.0 µM; LD50PBMC= 10.9 µM; LD50CD3+
T-cell = 4.4 µM; Fig. 1g), while EDO-S101 showed less activity
against normal CD3+ T cells and peripheral blood mono-
nuclear cells (PBMCs).
EDO-S101 also overcame milieu-mediated protection.
NKtert bone marrow stromal feeder cells were employed to
mimic such pro-survival conditions. In these co-cultures,
EDO-S101 potently induced apoptosis of T-PLL cells
(LD50T-PLL= 0.9 µM, LD50T-PLL+NKtert= 3.3 µM), more
than single-agent or combined vorinostat/bendamustine
treatment (Fig. 1h, S2d), while having hardly any effect on
NKtert cell viability at relevant concentrations (Fig. 1i).
Finally, EDO-S101 markedly reduced disease burden
and prolonged survival of tumor-bearing animals in models
of murine T-cell leukemia and lymphoma. Specifically,
activity of EDO-S101 in comparison to the clinically used
cytostatic agents bendamustine and fludarabine was asses-
sed in two distinct syngeneic transplant systems (Fig. 2a).
DBA2xC57/B6J F1 recipient mice, engrafted with
CD2-hMTCP1p13 tg leukemic T cells derived from the
CD2-hMTCP1p13 tg murine T-PLL model [6], were treated
with vehicle control, fludarabine (34 mg/kg at each injec-
tion), bendamustine (day 10: 60 mg/kg; days 15, 17, 19, 21
at 20 mg/kg), or with EDO-S101 (day 10: 50 mg/kg; days
15, 17, 19, 21 at 20 mg/kg). Leukemic burden and disease
progression were markedly suppressed by EDO-S101, as
indicated by significantly lower leukocyte counts and spleen
weights after treatment with EDO-S101 compared with
fludarabine or vehicle-control treated mice (Fig. 2b, c).
In the second transplant model (Fig. 2a), Rag1−/− mice
were engrafted with murine leukemic T-cells derived from
our system of Jak1-initiated mature T-cell lymphoma [16]
and treated with vehicle control, fludarabine, bendamustine,
or EDO-S101 (18 mg/kg each, days 7, 10, 13, 17, 22).
EDO-S101 reduced tumor burden and prolonged animal
survival as compared with bendamustine, fludarabine, and
vehicle control (e.g., EDO-S101 vs. all p= 0.039; Fig. 2d).
Notably, EDO-S101 had already shown superior antitumor
activity compared with cyclophosphamide treatment in
in vivo models of Burkitt’s lymphoma [15].
Overall, the data presented here suggest that insufficient
DDRs, in T-PLL constituted by hypomorphic ATM and
inactive p53, are shaped by a deregulation of de-/acetylating
enzymes. Thus, a combinatorial approach of DNA damage
induction and (H)DAC inhibition could serve as an effective
novel therapeutic principle in tumors with such a molecular
make-up. For that, EDO-S101, a molecule synergistically
combining DNA damage induction and inhibition of lesion
repair, represents a very promising strategy. Our in vitro data
also indicate an advantageous selectivity of EDO-S101
towards malignant over normal T-cells or PBMCs. More-
over, the presented in vivo studies demonstrate the efficacy
of EDO-S101 in systems similar to human T-PLL (i.e.
TCL1-family or JAK-initiated murine proliferations). Cur-
rently, patients with various advanced tumors are recruited
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into a phase I/II clinical trial (NCT03345485) with tinosta-
mustine (EDO-S101) to investigate safety, efficacy, and
pharmacokinetics of this new dual-action molecule. Those
with T-cell malignancies such as T-PLL appear particularly
suitable to benefit from this agent.
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Fig. 2 Anti-leukemic efficacy of EDO-S101 in vivo. a Transplant
models of murine T-cell leukemia/lymphoma used. Top: DBA2xC57/
B6J F1 recipient mice were engrafted with 1 × 107 CD2-hMTCP1p13
leukemic T-cells [6] and treated with the indicated substances starting
at 10 days thereafter. Lower panel: Rag1−/− mice were engrafted with
2.5 × 106 murine ΔJak1 transformed T-cells [16] and treated after
7 days with the indicated substances and dosages. b Leukocyte counts
in PB of CD2-hMTCP1p13 transplanted mice at day 9 and day 14 post
transplantation (n= 27 mice, unpaired t-test; mean with SEM).
c Postmortem spleen weights of CD2-hMTCP1p13 transplanted mice
(uniformly sacrificed at day 22) for the four treatment groups (n= 22
mice) show the superior effects of EDO-S101 (and single-agent
bendamustine) as compared with the fludarabine or control cohort
(EDO-S101 vs. ctrl: p= 0.19; fludarabine vs. ctrl: p= 0.14, unpaired
t-test; mean with SEM). d Injections of EDO-S101 (black arrows)
inhibited tumor growth and significantly prolonged animal survival
(n= 32 mice; log-rank; same-day events are due to necessary sacrifice)
in the ΔJak1 T-cell lymphoma model.
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